Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives

Frontiers in Oncology

Pedro Luiz Serrano Uson Junior¹  Miguel Zugman²  Roberto Carmagnani Pestana²  Gehan Botrus³ 

[1] Center for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil;Department of Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil;Medical Oncology Phase I Clinical Trials, HonorHealth Research Institute, Phoenix, AZ, United States;

关键词: cholangiocarcinoma;    FGFR2;    fusions;    precision medicine;    pemigatinib;   

DOI  :  10.3389/fonc.2022.860453

来源: DOAJ

【 摘 要 】

Although a relatively uncommon tumor, cholangiocarcinoma is on the rise globally. Of note, most patients are diagnosed with metastatic disease, and the prognosis is poor with cytotoxic chemotherapy. Strategies targeting specific genomic alterations have demonstrated promising activity in recent years and could represent a new therapeutic avenue for these patients. In this review, we will address the biology and clinical results of FGFR inhibition in intrahepatic cholangiocarcinoma, highlighting limitations associated with treatment and discussing the use of circulating tumor DNA to detect mechanisms of resistance.

【 授权许可】

Unknown